Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy

Neurotoxicology and Teratology

Volumn 34, Issue 3, 2012, Pages 303-310

  Singer, Lynn T ^a   Moore, Derek G ^b   Fulton, Sarah ^a   Goodwin, Julia ^b   Turner, John J D ^b   Min, Meeyoung O ^a   Parrott, Andrew C ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF EAST LONDON   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

"Ecstasy"; Drugs; Infant development; Methylenedioxymethamphetamine "MDMA"; Motor skills; Sex ratio; Townes Brocks

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; CANNABIS; CIGARETTE SMOKE; COCAINE; ILLICIT DRUG; KETAMINE; LYSERGIDE; OPIATE DERIVATIVE; PSYCHEDELIC AGENT; RECREATIONAL DRUG; TRANQUILIZER; OPIATE; STREET DRUG;

ADULT; ALBERTA INFANT MOTOR SCALES; ARTICLE; BAYLEY MENTAL AND MOTOR DEVELOPMENT SCALES; CHILD BEHAVIOR; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; EDUCATION; FEMALE; FOLLOW UP; HEALTH; HUMAN; INFANT; INFANT DISEASE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MOTOR DEVELOPMENT; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NEWBORN; NEWBORN DISEASE; NICU NETWORK NEUROBEHAVIORAL SCALE; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY; PROSPECTIVE STUDY; SEX RATIO; SOCIAL PROBLEM; WORK; ALBERTA INFANT MOTOR SCALE; BAYLEY MENTAL AND MOTOR DEVELOPMENT SCALE; BIRTH WEIGHT; CHILD DEVELOPMENT; CIGARETTE SMOKING; COGNITION; DOSE RESPONSE; DRUG USE; FIRST TRIMESTER PREGNANCY; LETHARGY; MOTOR PERFORMANCE; MUSCLE HYPOTONIA; NEUROPSYCHOLOGICAL TEST; PRENATAL DRUG EXPOSURE; PSYCHOMOTOR PERFORMANCE; RATING SCALE; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GESTATIONAL AGE; PREGNANCY; PREGNANCY OUTCOME; PSYCHOLOGICAL ASPECT;

ANIMALIA;

ADULT; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT BEHAVIOR; INFANT, NEWBORN; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; STREET DRUGS;

EID: 84859307193     PISSN: 08920362     EISSN: 18729738     Source Type: Journal    
DOI: 10.1016/j.ntt.2012.02.001     Document Type: Article

References (55)

1. Bayley N. Bayley Scales of Infant Development 1993, The Psychological Corporation, San Antonio, TX. 2nd ed.
2. Bronson M.E., Barrios-Zambrano L., Jiang W., Clark C.R., DeRuiter J., Newland M.C. Behavioral and developmental effects of two 3,4-methylenedioxymethamphetamine (MDMA) derivatives. Drug Alcohol Depend 1994, 36(3):161-166.
3. Cohen M.A., Skelton M.R., Schaefer T.L., Gudelsky G.A., Vorhees C.V., Williams M.T. Learning and memory after neonatal exposure to 3,4-methylenedioxymethamphetamine (ecstasy) in rats: interaction with exposure in adulthood. Synapse 2005, 57(3):148-159.
4. Crawford C.A., Williams M.T., Kohutek J.L., Choi F.Y., Yoshida S.T., McDougall S.A., et al. Neonatal 3,4-methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [(35)S]GTPgammaS binding in adult rats. Brain Res 2006, 1077:178-186.
5. Darrah J., Piper M., Watt M. Assessment of gross motor skills of at-risk infants: predictive validity of the Alberta Infant Motor Scale. Dev Med Child Neurol 1998, 40:485-491.
6. del Rio G., Marshall T., Tsai P., Shao Y.S., Guo Y.L. Number of boys born to men exposed to polychlorinated byphenyls. Lancet 2002, 360:143-144.
7. Derogatis L.R. The Brief Symptom Inventory Manual (BSI) 1992, Clinical Psychometric Research, Baltimore, MD.
8. Dumont G.J., Verkes R.J. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 2006, 20:176-187.
9. Fisk J.E., Montgomery C., Wareing M., Murphy P.N. Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology 2005, 181:550-559.
10. Freedman F.R., Johanson C., Tancer M.E. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2005, 183:248-256.
11. Grufferman S., Schwartz A.G., Ruymann F.B., Maurer H.M. Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 1993, 4(3):217-224.
12. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002, 162:396-405.
13. Hoshi R., Pratt H., Mehta S., Bond A.J., Curran H.V. An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences?. J. Psychophamacology 2006, 20:291-301.
14. Jacobs B.L., Fornal C.A. Serotonin and behaviour: a general hypothesis. Psychopharmacology 1995, 461-469. Raven Press Ltd., New York. F.E. Bloom, D.J. Kupfer (Eds.).
15. James W.H. Evidence that mammalian sex ratios at birth are partially controlled by parental hormone levels at the time of conception. J Theor Biol 1996, 180:271-286.
16. Johnston L.D., O'Mally P.M., Brachman J.G., Schulenberg J.F. Monitoring the future national survey results on drug use, 1975-2004. College students and adults ages 19-45 2005, Volume II. National Institute on Drug Abuse, Bethesda, MD, (NIH Publication No. 05-5728).
17. Kinsley C., Svare B. Prenatal stress alters maternal aggression in mice. Physiol Behav 1988, 42:7-13.
18. Kish S.J., Lerch J., Furukawa Y., Tong J., McCluskey T., Wilkins D., et al. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 2010, 133:1779-1797.
19. Koprich J.B., Chen E.Y., Kanaan N.M., Campbell N.G., Kordower J.H., Lipton J.W. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behaviour, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol 2003, 25(5):509-517.
20. Lester B.M., Tronick E.Z. The Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) - introduction. Pediatrics 2004, 113(3):641-667.
21. McCann U.D., Ricaurte G.A. Effects of (+/-) 3, 4-methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. Scientific World Journal 2007, 2:231-238.
22. McCann U.D., Sgambati F.P., Schwartz A.R., Ricaurte G.A. Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers. Neurology 2009, 73:2011-2017.
23. McElhatton P.R., Bateman D.N., Evans C., Pughe K.R., Thomas S.H. Congenital anomalies after prenatal ecstasy exposure. Lancet 1999, 354(9188):1441-1442.
24. Meyer J.S., Grande M., Johnson K., Ali S.F. Neurotoxic effects of MDMA ("ecstasy") administration to neonatal rats. Int J Dev Neurosci 2004, 22:261-271.
25. Milani R.M., Parrott A.C., Schifano F., Turner J.J. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Hum Psychopharmacol 2005, 20(4):249-261.
26. Mocarelli P., Gerthoux P.M., Ferrari E., Patterson D.G.J., Kieszak S.M., Brambilla P., et al. Paternal concentrations of dioxin and sex ratio of offspring. Lancet 2000, 355:1858-1863.
27. Moore D.G., Turner J.J.T., Parrott A.C., Goodwin J.E., Fulton S.E., Min M.O., et al. During pregnancy, recreational drug-using women stop taking ecstasy (MDMA) and reduce alcohol consumption but continue to smoke tobacco and cannabis: Initial findings from the DAISY study. J Psychopharmacol 2010, 24(9):1403-1410.
28. Moore D.G., Turner J.J.D., Goodwin J.E., Fulton S.E., Singer L.T., Parrott A.C. In-utero exposure to the popular 'recreational' drugs MDMA (Ecstasy) and methamphetamine (Ice, crystal): preliminary findings. Alcohol, drugs and medication in pregnancy: the long term outcome for the child 2011, 169-182. Mac Keith Press, London, England. P. Preece, E. Riley (Eds.).
29. Morefield K.M., Keane M., Felgate P., White J.M., Irvine R.J. The acute psychobiological impacts of illicit 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') consumption in recreational environments. Neuropsychobiology 2009, 60:216-217.
30. Parrott A.C. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002, 71:837-844.
31. Parrott A.C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bio-energetic stress. J Psychopharmacol 2006, 20:147-163.
32. Parrott A.C. Cortisol and MDMA: neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology 2009, 60:148-158.
33. Parrott A.C., Milani R., Parmar R., Turner J.J.D. Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 2001, 159:77-82.
34. Parrott A.C., Lock J., Conner A.C., Kissling C., Thome J. Dance clubbing on-MDMA and during abstinence from MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 2008, 57:165-180.
35. Piper M.C. Construction and validation of the Alberta Infant Motor Scale (AIMS). Can J Public Health 1992, 83(2):S46-S50.
36. Piper B.J. A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol 2007, 29(2):288-300.
37. Powell C.M., Michaelis R.C. Townes-Brocks syndrome. J Med Genet 1999, 36:89-93.
38. Reay J.L., Hamilton C., Kennedy D.O., Scholey A.B. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. J Psychopharmacol 2006, 20:385-388.
39. Rudnick G., Wall S.C. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 1992, 89(2):1817-1821.
40. Schaefer T.L., Skelton M.R., Herring N.R., Gudelsky G.A., Vorhees C.V., Williams M.T. Short- and long-term effects of (+)-methamphetamine and (+/-)-3,4-methylenedioxymethamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment. J Neurochem 2008, 104:1674-1685.
41. Singer L.T., Arendt R., Minnes S., Farkas K., Salvator A., Kirchner H.L., et al. Cognitive and motor outcomes of cocaine-exposed infants. J Am Med Assoc (JAMA) 2002, 287(287).
42. Singer L.T., Linares T.J., Ntiri S., Henry R., Minnes S. Psychosocial profiles of older adolescent MDMA users. Drug Alcohol Depend 2004, 74(3):245-252.
43. Skelton M.R., Williams M.T., Vorhees C.V. Developmental effects of 3,4-methylenedioxymethamphetamine: a review. Behav Pharmacol 2008, 19:91-111.
44. Skinner H.A. The Drug Abuse Screening Test (DAST). Addict Behav 1982, 7(4):363-371.
45. Smith L.M., LaGasse L.L., Derauf C., Newman E., Shah R., Haning W., et al. Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine. Neurotoxicol Teratol 2011, 33(1):176-184.
46. Tennes K., Avitable N., Blackard C., Boyles C., Hassoun B., Holmes L., et al. Marihuana: prenatal and postnatal exposure in the human. National institute on drug abuse 1985, 48-60. US Department of Health and Human Services, Rockville, MD. T.M. Pinkert (Ed.).
47. Terrell M.L., Berze A.K., Small C.M., Cameron L.L., Wirth J.J., Marcus M. A cohort study of the association between secondary sex ratio and parental exposure to polybrominated biphenyl (PBB) and polychlorinated biphenyl (PCB). Environ Health J 2009, 8:35.
48. Tildo T., Rignell-Hydbom A., Jonsson B., Giwercman Y.L., Rylander L., Hagmar L., et al. Exposure to persistent organochlorine polluntants associates with human sperm Y:X chromosome ratio. Hum Reprod 2005, 20(7):1903-1909.
49. Turner J.J.D., Nicolas L., Parrott A.C. Reduced calorie intake in the week following weekend MDMA (ecstasy) use. J Psychopharmacol 1998, 12:a43.
50. Vorhees C.V., Reed T.M., Skelton M.R., Williams M.T. Exposure to 3,4-methylenedioxymethamphetamine (MDMA) on postnatal days 11-20 induces reference but not working memory deficits in the Morris water maze in rats: implications of prior learning. Int J Dev Neurosci 2004, 22:247-259.
51. Vorhees C.V., Schaefer T.L., Williams M.T. Developmental effects of +/-3,4-methylenedioxymethamphetamine on spatial versus path integration learning: effects of dose distribution. Synapse 2007, 61:488-499.
52. Vorhees C.V., Schaefer T.L., Skelton M.R., Grace C.E., Herring N.R., Williams M.T. (+/-)3,4-Methylenedioxymethamphetamine (MDMA) dose-dependently impairs spatial learning in the Morris water maze after exposure of rats to different five-day intervals from birth to postnatal day twenty. Dev Neurosci 2009, 31:107-120.
53. Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI) 1999, Harcourt Assessment, San Antonio, TX.
54. Williams M.T., Morford L.L., Wood S.L., Rock S.L., McCrea A.E., Fukumura M., et al. Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects, or injection stress. Brain Res 2003, 968(89-01).
55. Wu P., Liu X., Pham T.H., Jin J., Fan B., Jin Z. Ecstasy use among US adolescents from 1999 to 2008. Drug Alcohol Depend 2010, 112(1-2):33-38.